Recipharm introduces end-to-end inhalation platform

Platform offers service from early stage development through commercial manufacturing

Photo as seen on company website

CDMO Recipharm has launched its end-to-end inhalation offering to provide customers with a fully integrated service from early stage development through to commercial manufacturing.

Recipharm Inhalation Solutions, which launched at Respiratory Drug Delivery Europe 2019, offers pharmaceutical companies an outsourcing service for inhalation products, including metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nasal sprays.

The offering follows the acquisition of Sanofi’s inhalation manufacturing business in Holmes Chapel, UK in June 2018, which has specialised in the manufacture of inhalation drug products for over 40 years. The facility is supported by Recipharm’s inhalation development expertise in Research Triangle Park, North Carolina, US.

Commenting on the announcement, Shabbir Mostafa, Global Key Account Director of Inhalations at Recipharm said: “Treatments for respiratory conditions are in high demand, making inhalation products a key growth area for our business. In addition to respiratory diseases, they are now being explored as alternative delivery routes to improve bioavailability and lower the risk of adverse effects, in treating, for instance, central nervous system conditions. This is making inhalation an interesting area for drug developers”.

"The Recipharm team has a long history in inhalation drug product development and manufacturing. This heritage, combined with market demand, made the launch of Recipharm Inhalation Solutions a logical step for us,” Mostafa added.

Recipharm Inhalation Solutions includes dedicated analytical services for inhalation products, including comprehensive extractable and leachable expertise.

A dedicated pilot facility for the platform is composed of several suites which can replicate commercial processes also assists with the ease of transfer of projects from small to large scale production. In addition, Recipharm has the technical experience to work with different devices, combinations, APIs and suspension formulations.

Companies